Core Insights - The article discusses the collaboration between government and enterprises in Shanghai, Zhejiang, and Anhui to promote the development of the high-end analytical testing reagent industry chain, marking a shift towards domestic production and reducing reliance on international giants [1][2]. Group 1: Industry Overview - The high-end analytical testing reagent market has been dominated by international companies, with over 80% market share held by foreign firms [1]. - Titan Technology, founded in 2007, has successfully overcome key challenges such as quality issues and reliance on core technologies, enabling the production of high-purity deuterated solvents domestically [1][2]. Group 2: Regional Collaboration - The signing ceremony involved market regulatory departments from Shanghai, Zhejiang, and Anhui, focusing on enhancing quality construction, standard cooperation, brand cultivation, and talent development within the industry [2][3]. - The collaboration aims to create a closed-loop ecosystem that integrates detection, research and development, and production, facilitating the industrialization of domestic alternatives [2][3]. Group 3: Product Innovation - Titan Technology launched five innovative products during the signing ceremony, covering analytical reagents, biological reagents, testing consumables, laboratory equipment, and intelligent laboratory systems [3]. - The company has achieved over 95% domestic substitution for laboratory products, with more than 7 million SKUs available on its sales platform [3].

Financial Data and Key Metrics Changes - For the third quarter of fiscal 2025, consolidated sales rose 1% year over year to $940 million, with modest volume growth offset by currency translation headwinds [9][20] - Adjusted EPS was $0.99, up approximately 8% compared to the prior year [10][21] - Operating margin improved by 80 basis points over the previous year, driven by expense leverage [9][21] Business Line Data and Key Metrics Changes - In Mobile Solutions, total sales were $583 million, roughly flat with the prior year, with aftermarket sales increasing by 3% to $460 million [13][14] - Industrial Solutions sales rose 5% to $283 million, with IFS sales at $232 million, a 1% increase from the prior year [15][16] - Life Sciences sales grew 1% to $74 million, with double-digit growth in disk drive and food and beverage replacement parts [16][17] Market Data and Key Metrics Changes - Mobile Solutions in China saw a 27% increase in sales, driven by growth in both first fit and aftermarket [15] - Aerospace and defense sales reached a record $52 million, largely due to robust market demand [7][16] - The impact of tariffs on net results was deemed immaterial for the quarter, with an annualized estimate of $35 million expected to be offset through supply chain and price adjustments [10][12] Company Strategy and Development Direction - The company is focused on long-term investments in technology opportunities and capital expenditures while maintaining a strong balance sheet [5][30] - A new COO was appointed to strengthen execution across the organization [6] - The company aims to navigate dynamic market conditions while advancing innovation and growth initiatives [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver long-term value despite macro uncertainties [4][35] - The company anticipates fiscal 2025 to be another record year, with record sales, operating margin, and adjusted earnings [17][34] - Management acknowledged ongoing market headwinds in bioprocessing but remains committed to strategic investments [23][24] Other Important Information - The company announced an 11% increase in its quarterly dividend, marking the 30th consecutive year of annual dividend increases [32][33] - Share repurchases totaled 2.4% of outstanding shares for $192 million during the quarter, with expectations to increase the full-year repurchase to between 3-4% [33] Q&A Session Summary Question: Can you discuss the gross profit margin dynamics and inflation impacts? - The decline in gross margin was primarily due to footprint optimization initiatives, with expectations to remain price-cost neutral [37][39][41] Question: What is driving the lowered CapEx outlook? - The company is prioritizing executing business operations over launching new CapEx projects due to supply chain pressures [42][44] Question: Can you provide insights on Industrial Solutions top-line trends? - The equipment side is pressured, but aftermarket growth and share gains in stationary hydraulics are offsetting challenges [49][51] Question: What is the visibility in aerospace and defense? - The company has long visibility on projects, but supply chain uncertainties make predictions challenging [62][68] Question: How does the company view the impact of tariffs on demand? - The company is managing carefully amidst uncertainties, with aftermarket and service-based businesses performing well [100][101]

5月26日，诺唯赞今日收盘21.34元，下跌2.33%，最新市净率2.18，总市值84.88亿元。 股东方面，截至2025年3月31日，诺唯赞股东户数8397户，较上次增加671户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入2.85亿元，同比-5.50%；净利润190.99万元，同 比-63.39%，销售毛利率69.40%。 南京诺唯赞生物科技股份有限公司的主营业务是围绕酶、抗原、抗体等功能性蛋白及高分子有机材料进 行技术研发和产品开发。公司的主要产品是生物试剂、诊断试剂、仪器设备、技术服务、耗材等材料。 来源：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)3诺唯赞-396.61-469.092.1884.88亿行业平均 48.9247.334.59105.60亿行业中值35.6837.002.4048.12亿1天益医疗-1741.60-2983.161.8622.19亿2澳华内 镜-632.39317.185.0766.65亿4爱朋医疗-353.16268.304.2528.98亿5博晖创新-319.03506.263.40 ...

证券研究报告 二、基本面：景气触底，盈利能力有望快速提升 2 添加标题 • 收入：增长平稳，持续修复。2024年科学服务核心标的收入平均同比增长7.17%，其中低耗类有较明显恢复性增长，仪器装备受到 capex减弱成长性受损，试剂及模式动物整体收入增长均在大个位数上下。2025年一季度科学服务核心标的收入平均增长6.29%， 整体行业景气与2024基本持平。其中化学试剂受到阿拉丁并购及皓元等新业务兑现影响，成长性有所提升。 点击此处添加标题添加标题点击此处添 • 毛利率：我们认为行业景气已基本触底，随着降本控费及产能利用率的提升，盈利能力有望逐渐修复。2024年科学服务核心标的毛 利率平均47.99%，其中生物试剂自24Q4起毛利率逐渐回升，行业竞争压力基本触底；模式动物随产能利用率提升，盈利能力进入 回升通道。2025年一季度科学服务核心标的毛利率平均48.05%，其中化学试剂、模式动物、耗材同比均有所提升。 加标题点击此处添加标题点击此处添加 标题点击此处添加标题点击此处添加标 • 资本开支：板块资本开支强度已进入近三年最低点，折旧摊销压力或明显减弱，进入投资收获期。2024年科学服务板块合计资本开 支为 ...